Infrequent epigenetic dysregulation of cip/kip family of cyclin-dependent kinase inhibitors in multiple myeloma

Access through your institution Buy or subscribe TO THE EDITOR Cell cycle progression is triggered by the activation of cyclin-dependent kinase 4/6 (CDK4/6) upon binding of cyclin D, and

further potentiated by subsequent activation of CDK2. On the other hand, the cell cycle is negatively regulated by the INK4 (p15, p16, p18 and p19) and the CIP/KIP (p21CIP, p27KIP1and

p57KIP2) families of cyclin-dependent kinase inhibitors (CKI).1 The INK4 family of CKIs bind to and inhibit CDK4/6.2 By contrast, the CKIs of the CIP/KIP family may bind to both CDK2 and

CDK4/6, and modulate their kinase activities. In quiescent cells, CIP/KIP CKIs bind to and inhibit the activity of CDK2, resulting in cell cycle arrest. In cycling cells, CKIs of the CIP/KIP

family detach from CDK2/cyclin E complex and bind to CDK4/6 instead, resulting in derepression (and thus activation) of CDK2 and further activation of CDK4/6, resulting in commitment of the

cell to transit the G1S cell cycle checkpoint.1 This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. * MULTIPLE

MYELOMA, A QUINTESSENTIAL MALIGNANT DISEASE OF AGING: A GEROSCIENCE PERSPECTIVE ON PATHOGENESIS AND TREATMENT * Veronika S. Urban * , Andrea Cegledi *  & Gabor Mikala _GeroScience_ Open

Access 12 December 2022 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more

Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Malumbres M, Barbacid M . To cycle or not to cycle: a critical decision in cancer.

_Nat Cancer Rev_ 2001; 1: 222–231. Article  CAS  Google Scholar  * Lee MH, Yang HY . Negative regulators of cyclin-dependent kinases and their roles in cancers. _Cell Mol Life Sci_ 2001; 58:

1907–1922. Article  CAS  Google Scholar  * Chim CS, Liang R, Kwong YL . Gene promoter hypermethylation in hematologic malignancies. _Hematol Oncol_ 2002; 20: 167–176. Article  CAS  Google

Scholar  * Chim CS, Fung TK, Cheung J, Liang R, Kwong YL . _SOCS1_ and _SHP1_ hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. _Blood_

2004; 103: 4630–4635. Article  CAS  Google Scholar  * Chim CS, Fung TK, Liang R . Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS.

_Leukemia_ 2003; 17: 2533–2535. Article  CAS  Google Scholar  * Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R et al. Promoter hypermethylation of the cyclin-dependent kinase

inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. _Blood_ 2004; 103: 743–746. Article  CAS  Google Scholar  * Shiohara M, el-Deiry WS, Wada M, Nakamaki T,

Takeuchi S, Yang R et al. Absence of WAF1 mutations in a variety of human malignancies. _Blood_ 1994; 84: 3781–3784. CAS  PubMed  Google Scholar  * Kawamata N, Morosetti R, Miller CW, Park

D, Spirin KS, Nakamaki T et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. _Cancer Res_ 1995; 55: 2266–2269. CAS  PubMed  Google Scholar

  * Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. _Nat Med_ 2002; 8:

1153–1160. Article  CAS  Google Scholar  * Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E et al. Aberrant DNA methylation of p57 (KIP2) gene in the promoter region in lymphoid malignancies

of B-cell phenotype. _Blood_ 2002; 100: 2572–2577. Article  CAS  Google Scholar  * Tetsu O, McCormick F . Proliferation of cancer cells despite CDK2 inhibition. _Cancer Cell_ 2003; 3:

233–245. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Dr Andrew Zannettino, Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Institute of

Medical and Veterinary Science, and Hanson Institute, Adelaide, Australia, for the six cell lines. We also thank Miss YY Chan and her team for the excellent nursing care of the patients.

AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong C S Chim, R Liang, T K Fung & Y L Kwong Authors * C S Chim

View author publications You can also search for this author inPubMed Google Scholar * R Liang View author publications You can also search for this author inPubMed Google Scholar * T K Fung

View author publications You can also search for this author inPubMed Google Scholar * Y L Kwong View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHORS Correspondence to C S Chim or Y L Kwong. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Chim, C., Liang, R., Fung, T. _et al._

Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. _Leukemia_ 19, 2352–2355 (2005). https://doi.org/10.1038/sj.leu.2403904

Download citation * Received: 16 June 2005 * Accepted: 01 July 2005 * Published: 10 November 2005 * Issue Date: December 2005 * DOI: https://doi.org/10.1038/sj.leu.2403904 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative